ICD10 code of 22q13 deletion / Phelan-McDermid Syndrome and ICD9 code

TL;DR: Phelan-McDermid syndrome (22q13 deletion syndrome) is classified under the ICD-10 code Q93.5 (other deletions of part of a chromosome) and the ICD-9 code 758.39 (other deletions of autosomes). These codes serve as administrative classifications for the condition, which is characterized by a deletion or mutation involving the SHANK3 gene on the terminal end of chromosome 22.

What is the clinical significance of the ICD codes for Phelan-McDermid syndrome?

While ICD-10 code Q93.5 and ICD-9 code 758.39 are the standard billing and tracking codes for Phelan-McDermid syndrome, they are broad classifications that encompass many different chromosomal deletions. Because 22q13 deletion is a rare genetic condition, these codes do not capture the specific clinical nuances of the syndrome, such as global developmental delay, absent or severely delayed speech, and neonatal hypotonia. In clinical practice, these codes are primarily used for insurance reimbursement and health system tracking, but they do not provide the granular detail required for personalized care management.

How is Phelan-McDermid syndrome formally diagnosed?

Diagnosis of Phelan-McDermid syndrome is confirmed through genetic testing, specifically chromosomal microarray (CMA) or targeted SHANK3 gene sequencing. While the ICD-10 code Q93.5 identifies the chromosomal abnormality, the clinical diagnosis relies on identifying a deletion of the 22q13.3 region or a pathogenic variant in the SHANK3 gene. Currently, at DiseaseMaps.org, 35 people with 22q13 deletion / Phelan-McDermid syndrome have joined our community, sharing their diagnostic journeys and lived experiences, which highlights the importance of genetic confirmation over simple ICD-based classification.

What are the common clinical features of 22q13 deletion?

Individuals with Phelan-McDermid syndrome present with a spectrum of symptoms that often require a multidisciplinary approach. The condition is frequently associated with specific neurodevelopmental and physical traits, including:

• Severe speech delay or complete absence of expressive language.


• Moderate to profound intellectual disability.


• Neonatal hypotonia (low muscle tone) and motor delays.


• Distinctive minor dysmorphic features, such as fleshy hands or dysplastic toenails.


• A high prevalence of autism spectrum disorder (ASD) traits.


• Increased risk of seizures, which occur in approximately 25% to 40% of diagnosed individuals.

Is Phelan-McDermid syndrome hereditary?

Most cases of Phelan-McDermid syndrome are de novo, meaning the genetic change occurs spontaneously in the egg or sperm and is not inherited from either parent. However, in a small percentage of cases, a parent may carry a balanced translocation or other structural rearrangement involving the 22q13 region, which can increase the risk of recurrence in future pregnancies. Genetic counseling is strongly recommended for families to understand the specific inheritance pattern of their child's 22q13 deletion.

Next steps

• Consult with a clinical geneticist to review microarray results and discuss familial testing.


• Establish care with a multidisciplinary team including neurologists, speech therapists, and developmental pediatricians.


• Connect with the 35 members of the Phelan-McDermid syndrome community on DiseaseMaps.org to share resources and coping strategies.


• Register with the Phelan-McDermid Syndrome Foundation (PMSF) to access the latest clinical trial information and family support networks.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• Orphanet: Phelan-McDermid syndrome (ORPHA:2767).


• NIH Genetic and Rare Diseases Information Center (GARD): 22q13 deletion syndrome.


• OMIM (Online Mendelian Inheritance in Man): Phelan-McDermid syndrome (#606232).


• Phelan-McDermid Syndrome Foundation (PMSF): Clinical and research resources.